ATE418334T1 - Enol-tautomer der 3-indol-brenztraubensäure in fester und im wesentlichen reiner form zur behandlung von erkrankungen des zentralen nervensystems - Google Patents

Enol-tautomer der 3-indol-brenztraubensäure in fester und im wesentlichen reiner form zur behandlung von erkrankungen des zentralen nervensystems

Info

Publication number: ATE418334T1
Authority: AT; Austria
Prior art keywords: enol tautomer; pure form; acid; pyrufuric; indole
Prior art date: 2002-05-09

Application number

AT03727938T

Other languages

English (en)

Inventor

Vincenzo Politi

Antonio Sella

Barbara Bartolini

Andrea Margonelli

Francesca Somma

Cristina Corniello

Original Assignee

Polifarma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-09

Filing date

2003-05-07

Publication date

2009-01-15

2003-05-07 Application filed by Polifarma Spa filed Critical Polifarma Spa

2009-01-15 Application granted granted Critical

2009-01-15 Publication of ATE418334T1 publication Critical patent/ATE418334T1/de

Links

150000002085 enols Chemical class 0.000 title abstract 3
239000002253 acid Substances 0.000 title 1
210000003169 central nervous system Anatomy 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000007787 solid Substances 0.000 title 1
230000000144 pharmacologic effect Effects 0.000 abstract 2
RSTKLPZEZYGQPY-UHFFFAOYSA-N 3-(indol-3-yl)pyruvic acid Chemical compound C1=CC=C2C(CC(=O)C(=O)O)=CNC2=C1 RSTKLPZEZYGQPY-UHFFFAOYSA-N 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
239000003513 alkali Substances 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)

AT03727938T 2002-05-09 2003-05-07 Enol-tautomer der 3-indol-brenztraubensäure in fester und im wesentlichen reiner form zur behandlung von erkrankungen des zentralen nervensystems ATE418334T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT2002RM000255A ITRM20020255A1 (it)	2002-05-09	2002-05-09	Tautomero enolico dell'acido 3-indolilpiruvico, suoi sali e usi terapeutici.

Publications (1)

Publication Number	Publication Date
ATE418334T1 true ATE418334T1 (de)	2009-01-15

Family

ID=11456293

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03727938T ATE418334T1 (de)	2002-05-09	2003-05-07	Enol-tautomer der 3-indol-brenztraubensäure in fester und im wesentlichen reiner form zur behandlung von erkrankungen des zentralen nervensystems

Country Status (11)

Country	Link
US (1)	US20050208125A1 (de)
EP (1)	EP1501503B1 (de)
JP (1)	JP2005529146A (de)
KR (1)	KR20040108787A (de)
CN (1)	CN100588398C (de)
AT (1)	ATE418334T1 (de)
AU (1)	AU2003233183A1 (de)
CA (1)	CA2483991A1 (de)
DE (1)	DE60325468D1 (de)
IT (1)	ITRM20020255A1 (de)
WO (1)	WO2003094914A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2020012373A1 (en) *	2018-07-10	2020-01-16	Polindols S.R.L.S.	New drugs chronic invalidating pathologies and to slow aging, based on a new metabolic tryptophan route and production process thereof
WO2021149806A1 (en) *	2020-01-24	2021-07-29	Morinaga Milk Industry Co., Ltd.	Composition for improving neurite outgrowth
AU2021329906A1 (en)	2020-08-18	2023-04-27	Enviro Metals, LLC	Metal refinement
CN115813919B (zh) *	2022-12-08	2024-02-06	佛山市妇幼保健院	吲哚-3-丙酮酸或其药用盐在制备治疗乳腺癌药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1482844A (fr) *	1964-12-31	1967-06-02	Merck & Co Inc	Procédé de préparation de nouveaux acides 2-[2-(phénylalkyl substitué)-3-indolyl] aliphatiques inférieurs
FR2306693A1 (fr) *	1975-04-11	1976-11-05	Roussel Uclaf	Nouveaux derives du /9h/pyrido/3,4-b/ indole et leurs sels, procede de preparation et application a titre de medicaments
US4822812A (en) *	1987-05-21	1989-04-18	Merrell Dow Pharmaceuticals Inc.	β-(Fluoromethylene)-5-hydroxytryptophan and derivatives and their use as prodrugs for MAO inhibition
IT1237472B (it) *	1989-10-04	1993-06-07	Polifarma Spa	Derivati di acido 3-indolpiruvico, loro procedimento di produzione ed impiego terapeutico.
TW288010B (de) *	1992-03-05	1996-10-11	Pfizer

2002
- 2002-05-09 IT IT2002RM000255A patent/ITRM20020255A1/it unknown
2003
- 2003-05-07 EP EP03727938A patent/EP1501503B1/de not_active Expired - Lifetime
- 2003-05-07 WO PCT/IT2003/000275 patent/WO2003094914A1/en not_active Ceased
- 2003-05-07 CA CA002483991A patent/CA2483991A1/en not_active Abandoned
- 2003-05-07 US US10/513,859 patent/US20050208125A1/en not_active Abandoned
- 2003-05-07 AT AT03727938T patent/ATE418334T1/de not_active IP Right Cessation
- 2003-05-07 CN CN03810540A patent/CN100588398C/zh not_active Expired - Fee Related
- 2003-05-07 DE DE60325468T patent/DE60325468D1/de not_active Expired - Lifetime
- 2003-05-07 JP JP2004503000A patent/JP2005529146A/ja active Pending
- 2003-05-07 AU AU2003233183A patent/AU2003233183A1/en not_active Abandoned
- 2003-05-07 KR KR10-2004-7018015A patent/KR20040108787A/ko not_active Ceased

Also Published As

Publication number	Publication date
EP1501503A1 (de)	2005-02-02
JP2005529146A (ja)	2005-09-29
CN100588398C (zh)	2010-02-10
CA2483991A1 (en)	2003-11-20
CN1652773A (zh)	2005-08-10
WO2003094914A1 (en)	2003-11-20
KR20040108787A (ko)	2004-12-24
AU2003233183A1 (en)	2003-11-11
EP1501503B1 (de)	2008-12-24
DE60325468D1 (de)	2009-02-05
ITRM20020255A1 (it)	2003-11-10
ITRM20020255A0 (it)	2002-05-09
US20050208125A1 (en)	2005-09-22

Legal Events

Date	Code	Title	Description
2009-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
NL300933I2 (nl)	2018-04-26	Letermovir
BR0310106A (pt)	2005-02-22	Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
MXPA03011484A (es)	2004-03-18	Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
BRPI0408369A (pt)	2006-03-21	derivados de indol úteis para o tratamento de doenças
DE60229267D1 (de)	2008-11-20	Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
CY1109104T1 (el)	2014-07-02	1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
ATE455763T1 (de)	2010-02-15	Piperidine und verwandte verbindungen zur behandlung von alzheimer-krankheit
ATE485258T1 (de)	2010-11-15	Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11- beta-hydroxysteroid dehydrogenase
CY1111327T1 (el)	2015-08-05	Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
CY1110711T1 (el)	2015-06-10	Παραγωγα πυραζολο [3,4-d]αζεπινης ως ανταγωνιστες ισταμινης η3
ATE432278T1 (de)	2009-06-15	Verbindungen zur behandlung von krankheiten
DE60222286D1 (de)	2007-10-18	Verfahren zur erhöhung des testosteronspiegels
ATE367380T1 (de)	2007-08-15	Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
ATE418334T1 (de)	2009-01-15	Enol-tautomer der 3-indol-brenztraubensäure in fester und im wesentlichen reiner form zur behandlung von erkrankungen des zentralen nervensystems
DE602005027677D1 (de)	2011-06-09	1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
PL1745010T3 (pl)	2010-01-29	Podstawione pochodne cykloheksylo-1,4-diaminy
NO20061828L (no)	2006-06-28	Nye derivater av 4A,5,9,10,11,12-heksahydrobenzofuro[3A,3,2][2]-benzazepin, fremgangsmate for fremstilling derav og anvendelse derav ved fremstilling av medikamenter
ATE424195T1 (de)	2009-03-15	Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
ATE496534T1 (de)	2011-02-15	Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden
ATE437855T1 (de)	2009-08-15	(4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
DE602004025935D1 (de)	2010-04-22	Histondeacetylaseinhibitor und verfahren zu dessen herstellung
TW200505830A (en)	2005-02-16	Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
ATE334980T1 (de)	2006-08-15	Verfahren zur herstellung von 2-methyl piperazine derivaten.
EA200600115A1 (ru)	2008-06-30	Производные 2-аминобензойной кислоты
DE602005005218D1 (de)	2008-04-17	Kristalline form von cefdinir-ammoniumsalz als zwischenprodukt für die herstellung von reinem cefdinir